Identification

Name
Fluspirilene
Accession Number
DB04842
Type
Small Molecule
Groups
Approved, Investigational
Description

A long-acting injectable antipsychotic agent used for chronic schizophrenia.

Structure
Thumb
Synonyms
  • Fluspirileno
  • Fluspirilenum
  • Imap
External IDs
Lopac-F-100 / MCN-JR-6218 / R 6218
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Imap Forte Inj 10mg/mlSuspension10 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1982-12-311998-08-13Canada
Imap Inj 2mg/mlSuspension2 mgIntramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1977-12-311998-03-12Canada
International/Other Brands
Imap (Janssen) / lmap (McNeil) / Redeptin (SKF)
Categories
UNII
C5QA4GLR9M
CAS number
1841-19-6
Weight
Average: 475.5727
Monoisotopic: 475.243519039
Chemical Formula
C29H31F2N3O
InChI Key
QOYHHIBFXOOADH-UHFFFAOYSA-N
InChI
InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
IUPAC Name
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
SMILES
FC1=CC=C(C=C1)C(CCCN1CCC2(CC1)N(CNC2=O)C1=CC=CC=C1)C1=CC=C(F)C=C1

Pharmacology

Indication

Used for the treatment of schizophrenia.

Pharmacodynamics

Fluspirilene is a relatively long-acting injectable depot antipsychotic drug used for schizophrenia. Fluspirilene does not differ greatly from other depot antipsychotics (fluphenazine decanoate, fluphenazine enathate, perphenazine onanthat, pipotiazine undecylenate) with respect to treatment efficacy, response or tolerability. Outcomes suggest that fluspirilene does not differ significantly from oral antipsychotics or in different weekly regimens, although much cannot be inferred because of the shortage of trials.

Mechanism of action
TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
UVoltage-dependent calcium channel gamma-1 subunit
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Fluspirilene.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Fluspirilene.Vet Approved
2,5-Dimethoxy-4-ethylamphetamineFluspirilene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineFluspirilene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFluspirilene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluspirilene.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluspirilene.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluspirilene.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluspirilene.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Fluspirilene.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluspirilene.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.Approved, Illicit, Investigational
AmisulprideFluspirilene may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluspirilene.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluspirilene.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Fluspirilene.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluspirilene.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amperozide.Experimental
AmphetamineFluspirilene may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Fluspirilene.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Fluspirilene.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Fluspirilene.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Fluspirilene.Approved
ArticaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluspirilene.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Azaperone.Investigational, Vet Approved
AzelastineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluspirilene.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Fluspirilene.Experimental
BarbexacloneThe metabolism of Fluspirilene can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluspirilene.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Fluspirilene.Approved, Investigational
BenzphetamineFluspirilene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Fluspirilene.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Fluspirilene.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Fluspirilene.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Fluspirilene.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluspirilene.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluspirilene.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Fluspirilene.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Fluspirilene.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.Approved, Investigational
BuprenorphineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluspirilene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluspirilene.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Fluspirilene.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluspirilene.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Fluspirilene.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluspirilene.Approved
Calcium AcetateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Fluspirilene.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Fluspirilene.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluspirilene.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Fluspirilene.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluspirilene.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluspirilene.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Fluspirilene.Approved, Investigational
CaseinThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Fluspirilene.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Fluspirilene.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluspirilene.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluspirilene.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluspirilene.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluspirilene.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Fluspirilene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Fluspirilene.Approved
ChlorphentermineFluspirilene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluspirilene.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluspirilene.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Fluspirilene.Approved, Investigational
CimetidineThe serum concentration of Fluspirilene can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Fluspirilene.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluspirilene.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluspirilene.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluspirilene.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluspirilene.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluspirilene.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fluspirilene.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluspirilene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clothiapine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Fluspirilene.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluspirilene.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluspirilene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Fluspirilene.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluspirilene.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fluspirilene.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluspirilene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluspirilene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluspirilene.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluspirilene.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluspirilene.Approved, Vet Approved
DextroamphetamineFluspirilene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluspirilene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluspirilene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluspirilene.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluspirilene.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Fluspirilene.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Diethyl ether.Experimental
DiethylpropionFluspirilene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluspirilene.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluspirilene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluspirilene.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluspirilene.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluspirilene.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluspirilene.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Fluspirilene.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluspirilene.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fluspirilene is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Fluspirilene.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluspirilene.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluspirilene.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Fluspirilene.Approved
EcopipamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Fluspirilene can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Fluspirilene.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluspirilene.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluspirilene.Approved, Investigational
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Fluspirilene.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluspirilene.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluspirilene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluspirilene.Approved, Investigational
EthanolFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluspirilene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluspirilene.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluspirilene.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluspirilene.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluspirilene.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluspirilene.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluspirilene.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Fluspirilene.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Fluspirilene.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluspirilene.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluspirilene.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Fluspirilene.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Fluspirilene.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluspirilene.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluanisone.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Fluspirilene.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluspirilene.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluspirilene.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluspirilene.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluspirilene.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene.Approved, Illicit, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluspirilene.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Fluspirilene.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluspirilene.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Fluspirilene.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluspirilene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fluspirilene.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluspirilene.Approved, Illicit, Investigational
GepefrineFluspirilene may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluspirilene.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Fluspirilene.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluspirilene.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Fluspirilene.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluspirilene.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Fluspirilene.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluspirilene.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Fluspirilene.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluspirilene.Approved
HydrocodoneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluspirilene.Approved, Illicit
HydroxyamphetamineFluspirilene may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fluspirilene.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluspirilene.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Fluspirilene.Withdrawn
Iofetamine I-123Fluspirilene may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Fluspirilene can be increased when used in combination with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Fluspirilene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluspirilene.Approved, Vet Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Fluspirilene.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluspirilene.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluspirilene.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluspirilene.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluspirilene.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fluspirilene.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluspirilene.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluspirilene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluspirilene.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluspirilene.Approved, Investigational
LisdexamfetamineFluspirilene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Fluspirilene.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Fluspirilene can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluspirilene.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluspirilene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluspirilene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluspirilene.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Fluspirilene can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluspirilene.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluspirilene.Approved
MedazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluspirilene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Fluspirilene.Experimental
MephedroneFluspirilene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFluspirilene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Meptazinol.Experimental
MequitazineFluspirilene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluspirilene.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluspirilene.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluspirilene.Approved, Illicit
MethamphetamineFluspirilene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluspirilene.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluspirilene.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluspirilene.Approved
MethotrimeprazineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluspirilene.Approved, Investigational, Vet Approved
MethoxyphenamineFluspirilene may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluspirilene.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluspirilene.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluspirilene.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.Approved, Investigational
MetyrosineFluspirilene may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Fluspirilene.Experimental
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Fluspirilene.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.Approved, Illicit
MidomafetamineFluspirilene may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Fluspirilene.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
MirtazapineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAFluspirilene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluspirilene.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Fluspirilene.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Fluspirilene.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
NafcillinThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Fluspirilene.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluspirilene.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.Approved, Investigational
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Fluspirilene.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nefazodone.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Fluspirilene.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Fluspirilene.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Fluspirilene.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Fluspirilene.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Fluspirilene.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.Approved
NitroprussideFluspirilene may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluspirilene.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Fluspirilene.Approved
NordazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluspirilene.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Fluspirilene.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluspirilene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluspirilene.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Fluspirilene.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluspirilene.Approved
OpiumThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Opium.Approved, Illicit
OrphenadrineFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Fluspirilene.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluspirilene.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluspirilene.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Fluspirilene.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluspirilene.Approved
ParaldehydeFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Fluspirilene.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluspirilene.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
PerazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluspirilene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluspirilene.Approved
PhenibutThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluspirilene.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Fluspirilene.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenoxyethanol.Approved
PhentermineFluspirilene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Fluspirilene.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Fluspirilene.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluspirilene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluspirilene.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluspirilene.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluspirilene.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
PramipexoleFluspirilene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Fluspirilene.Approved
PregabalinThe therapeutic efficacy of Fluspirilene can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluspirilene.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fluspirilene.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluspirilene.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluspirilene.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluspirilene.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluspirilene.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Fluspirilene.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Fluspirilene.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Fluspirilene.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluspirilene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Fluspirilene is combined with PSD502.Investigational
PseudoephedrineFluspirilene may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Fluspirilene.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluspirilene.Approved, Investigational
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Fluspirilene.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Quinisocaine.Experimental
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Fluspirilene.Approved
RacloprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Fluspirilene.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluspirilene.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluspirilene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluspirilene.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Fluspirilene.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Fluspirilene.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Fluspirilene.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Fluspirilene.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ritanserin.Investigational
RitobegronFluspirilene may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluspirilene.Approved
RomifidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Romifidine.Vet Approved
RopiniroleFluspirilene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene.Approved
RotigotineFluspirilene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluspirilene.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Fluspirilene.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluspirilene.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluspirilene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluspirilene.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Fluspirilene.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Fluspirilene.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Fluspirilene.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Fluspirilene.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Fluspirilene.Approved
SulpirideFluspirilene may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluspirilene.Approved, Investigational
SuvorexantFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Fluspirilene.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluspirilene.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Fluspirilene.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluspirilene.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluspirilene.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Fluspirilene.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Fluspirilene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluspirilene.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrodotoxin.Investigational
ThalidomideFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluspirilene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluspirilene.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Fluspirilene.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluspirilene.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Fluspirilene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluspirilene.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Fluspirilene.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Fluspirilene.Approved, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Fluspirilene.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluspirilene.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Fluspirilene.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Fluspirilene.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluspirilene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluspirilene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluspirilene.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluspirilene.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Fluspirilene.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Fluspirilene.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluspirilene.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Fluspirilene.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluspirilene.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Fluspirilene.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Fluspirilene.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluspirilene.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluspirilene.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vinyl ether.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Fluspirilene.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vortioxetine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Fluspirilene.Experimental
XenonThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluspirilene.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fluspirilene.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene.Approved, Investigational
ZolpidemFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluspirilene.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluspirilene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene.Approved, Investigational
Food Interactions
  • Avoid alcohol.

References

Synthesis Reference

Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3238216
General References
Not Available
External Links
Human Metabolome Database
HMDB0015590
KEGG Drug
D02629
PubChem Compound
3396
PubChem Substance
46508202
ChemSpider
3279
BindingDB
26948
ChEBI
93369
ChEMBL
CHEMBL46516
Therapeutic Targets Database
DAP000980
PharmGKB
PA162565878
IUPHAR
85
Guide to Pharmacology
GtP Drug Page
Wikipedia
Fluspirilene
ATC Codes
N05AG01 — Fluspirilene

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular10 mg
SuspensionIntramuscular2 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)187.5-190Janssen, P.A.J.; U.S. Patent 3,238,216; March 1, 1966; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility10 mg/L (at 25 °C)MERCK INDEX (1996)
logP5.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00167 mg/mLALOGPS
logP5.18ALOGPS
logP5.78ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.99ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity135.27 m3·mol-1ChemAxon
Polarizability50.88 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9807
Blood Brain Barrier+0.9713
Caco-2 permeable-0.68
P-glycoprotein substrateSubstrate0.7042
P-glycoprotein inhibitor IInhibitor0.9082
P-glycoprotein inhibitor IIInhibitor0.8257
Renal organic cation transporterInhibitor0.5978
CYP450 2C9 substrateNon-substrate0.835
CYP450 2D6 substrateNon-substrate0.5726
CYP450 3A4 substrateSubstrate0.645
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9209
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.6989
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7201
Ames testNon AMES toxic0.5428
CarcinogenicityNon-carcinogens0.8871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6387 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8401
hERG inhibition (predictor II)Inhibitor0.9014
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006t-9636300000-e318745a9958ecf316e7

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylbutylamines / Phenylimidazolidines / Alpha amino acids and derivatives / Azaspirodecane derivatives / Dialkylarylamines / Aniline and substituted anilines / Fluorobenzenes / Aralkylamines / Imidazolidinones / Aryl fluorides
show 10 more
Substituents
Diphenylmethane / Phenylbutylamine / Phenylimidazolidine / Alpha-amino acid or derivatives / Azaspirodecane / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine / Halobenzene / Fluorobenzene
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444]
  5. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Kenny BA, Fraser S, Kilpatrick AT, Spedding M: Selective antagonism of calcium channel activators by fluspirilene. Br J Pharmacol. 1990 Jun;100(2):211-6. [PubMed:1696149]
  2. Wang SJ: Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. [PubMed:11842444]

Drug created on September 27, 2007 07:56 / Updated on July 02, 2018 18:22